Independent Director — Disposable Hygiene-Products Manufacturer | IPO Audit, Product Safety & Concentration Risk

Reference: GILA/7BM/IPO02/100826
Entity: Indian disposable consumer-hygiene manufacturer preparing for an IPO; client confidential
Seat: Independent Director; intended Audit Committee Chair and member of Risk/CSR or Sustainability Committee
Primary geography: Indore / Mumbai, with mandatory visits to manufacturing locations in central India
Expected cadence before listing: Monthly IPO-readiness session; 6 Board meetings; 6 Audit meetings; 3 plant/quality reviews; normalised cadence after the first listed year

Anonymised IPO-entrant profile

The company manufactures disposable consumer-hygiene products, with baby diapers currently contributing roughly three-quarters to four-fifths of revenue and adjacent adult-care or feminine-hygiene lines providing diversification potential. Public filing research on a comparable current entrant indicates annual revenue in the broad ₹1,000–1,300 crore range, four manufacturing units concentrated in one central Indian state, a predominantly domestic business and early exports to the Middle East and Africa.

The commercial model includes private-label or contracted manufacturing for large customers as well as owned or developing brands. Customer and supplier concentration are material: a small group of customers contributes most revenue, while key absorbent materials, non-wovens, films, elastic components and equipment have import or limited-source exposure. The contemplated offer includes fresh capital and a secondary component.

Calibrated market hint: A four-plant central-India footprint, baby-care concentration and relationships with large mother-and-baby retail or distribution platforms may suggest a small set of manufacturers. Exact mix, customer identity, town and capacity are intentionally withheld.

Why this seat exists now

The IPO story requires the Board to distinguish fast revenue growth from durable bargaining power. A large customer can simultaneously be strategic, related, concentrated and economically dominant. Product quality failures may affect infants or medically vulnerable adults. Imported inputs, machine dependence, working-capital expansion and a proposed acquisition agenda amplify the consequence of weak controls. The new director must establish public-market-grade audit and product stewardship before the offer is launched.

Strategic charter — pre-IPO through first listed year

1. Validate revenue by customer, contract, purchase order, dispatch, acceptance, returns, rebates, price protection, promotional support and collection; investigate quarter-end cut-off and channel stock.
2. Put concentrated and connected customers under enhanced independent governance: arm’s-length pricing, credit terms, forecasts, contract renewal, rebates, exclusivity, data access and downside if volumes move.
3. Establish customer-concentration appetite and de-risking milestones based on gross profit, cash conversion and replacement difficulty—not revenue percentages alone.
4. Build end-to-end product-safety controls for absorbency, skin compatibility, microbiological risk, chemical restrictions, foreign matter, adhesive and elastic performance, packaging integrity, traceability, complaints and recall.
5. Require supplier and raw-material qualification by criticality, substitutability, country, currency, lead time, quality history and geopolitical exposure; test approved alternative formulations before crisis use.
6. Link capacity and line-speed expansion to stable process capability, yield, scrap, downtime, labour competence, demand commitments and cash return; prevent volume pressure from weakening inspection or maintenance.
7. Govern inventory and working capital by raw material, work in progress, finished goods, customer-specific stock, ageing, obsolescence and import pipeline; stress-test freight, currency and demand cancellation together.
8. Separate owned-brand and contract-manufacturing economics, including advertising, distributor margin, consumer returns, bad debts and incremental working capital; set disciplined incubation and exit gates.
9. Review acquisitions against technology, customer access, integration capacity, contingent liability, quality systems and return thresholds; do not use IPO proceeds to purchase growth that obscures concentration.
10. Prepare export governance for product registration, labelling, sanctions, distributor credit, recalls, local standards and adverse-event handling in each target market.
11. Measure environmental exposure from polymer use, packaging, manufacturing waste, water, energy and emerging extended-producer obligations; challenge unverifiable biodegradability or sustainability claims.
12. Install IPO controls covering restated accounts, related parties, internal financial controls, whistle-blower access, insider trading, material events, proceeds tracking and first-year results.

Decisions expected before and soon after listing

• Whether the offer document describes a customer relationship as arm’s-length and durable when pricing power, related-party history or termination rights tell a more complex story.
• Whether a new high-speed line should be commissioned before alternative raw materials and process capability are proven.
• Whether diversification into an adjacent hygiene category is commercially independent or relies on the same concentrated customer.
• Whether an acquisition funded from fresh proceeds passes return and quality diligence without optimistic synergies.

Candidate evidence sought

Essential: Listed Audit Committee chair, consumer/health-products CEO or CFO, regulated manufacturing/quality leader, or public-markets professional with IPO and plant-governance experience; deep revenue, related-party, working-capital and capex judgement; product-safety/recall experience involving sensitive consumers; ability to challenge a powerful customer or shareholder relationship without destabilising legitimate trade.

Differentiators: disposable hygiene, medical consumables, food, pharma packaging or other high-volume quality-controlled manufacturing; private-label economics; imported polymer/non-woven sourcing; brand incubation; emerging-market exports.

Mandatory IICA and IPO eligibility gate

• Only candidates with active IICA Independent Directors Databank inclusion at application and appointment are eligible. GILA will not place an unregistered candidate on the IPO slate.
• The applicable IICA proficiency test must have been passed or a valid exemption must be documented.
• Companies Act independence, DIN/KYC, disqualification and directorship/committee-capacity checks are compulsory, together with eligibility for the intended post-listing Board under prevailing SEBI requirements.
• Audit Committee financial literacy and the experience required to chair complex financial reporting must be evidenced, not inferred from title.

Conflict and independence screen

Candidates must disclose relationships with promoters or significant shareholders, major customers and their affiliates, selling holders, lead managers, lenders, auditors, law firms, distributors, polymer and non-woven suppliers, equipment vendors, testing laboratories, certification bodies and competitors. Previous advisory work on the IPO, related-party arrangements, quality certification or acquisition targets requires specific cooling-off and independence analysis.

Candidate-side diligence before consent

Shortlisted candidates will receive the draft offer document, restated financials, customer and supplier concentration by revenue/gross profit/cash, related-party history, contracts, returns and rebates, quality and complaint trends, product tests, plant-capability data, open litigation, tax, environmental consents, capex and acquisition papers, proceeds schedule and D&O cover. Plant visits will include traceability and recall simulation, not only a management presentation.

Outcomes expected by listing / month 12

• Independently supportable revenue, related-party and concentration disclosures with no unresolved cut-off issues.
• Board-approved product-safety and recall architecture tested from raw-material lot to affected customer.
• Credible customer and supplier de-risking milestones tied to margin and cash, not vanity diversification.
• Fresh proceeds tracked to approved objects with acquisition and capex gates; first-year reporting delivered without material control surprise.

Portfolio-wide application and assessment protocol

Mandatory documents at application

1. Evidence of active IICA Independent Directors Databank inclusion and test-passed status or valid exemption.
2. Current DIN and KYC status; complete directorship and committee schedule, including unlisted and overseas entities.
3. A five-year relationship and assignment disclosure covering the anonymised sector, likely counterparties, auditors, advisers and significant shareholders.
4. Securities, financial-interest and close-relative disclosures sufficient for client-specific conflict testing.
5. Two Board-level referees able to discuss challenge, judgement, confidentiality and behaviour under pressure.

Assessment method

Candidates will be assessed through a mandate-specific Board case, conflict interview, evidence-based career review and consent-readiness discussion. GILA will not recommend a candidate merely because the person is eminent, retired from a large institution or registered in the Databank. Registration establishes eligibility; it does not establish independence of mind, sector judgement, capacity or courage.

Appointment safeguards

Before consent, the selected candidate should receive the proposed appointment letter, committee charter, expected calendar, information rights, familiarisation plan, D&O policy, indemnity where lawful, open regulatory/litigation matters and the most recent Board evaluation. Formal appointment remains subject to the company’s NRC and Board process, shareholder approval where required, regulatory clearance where applicable and all prevailing law.